Ignite Creation Date:
2024-05-06 @ 7:52 PM
Last Modification Date:
2024-10-26 @ 3:15 PM
Study NCT ID:
NCT06160895
Status:
RECRUITING
Last Update Posted:
2024-01-03
First Post:
2023-11-30
Brief Title:
A Clinical Trial of TQ-A3334 Tablet After Multiple Administration in Adult Subjects
Sponsor:
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Organization:
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Study Overview
Official Title:
Phase I Clinical Trial to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of TQ-A3334 Tablet After Multiple Doses in Healthy Adult Subjects
Status:
RECRUITING
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a randomized double-blind placebo-controlled Phase I clinical study of TQ-A3334 tablets in adult healthy subjects and the trial is planned to enroll 90 healthy subjects
The primary objective is to evaluate the safety and tolerability of TQ-A3334 tablets after multiple doses in healthy subjects
The primary objective is to evaluate the safety and tolerability of TQ-A3334 tablets after multiple doses in healthy subjects
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None